Serum Prostate-Specific Antigen as a Predictor of Prostate Volume in Men with Benign Prostatic Hyperplasia.
- Author:
Dong Soo RYU
1
;
Byung Hwan KIM
;
Woo Jin PARK
;
Jun O KWON
;
Tae Hee OH
Author Information
1. Department of Urology, Sungkyunkwan University School of Medicine, Masan Samsung Hospital, Masan, Korea. natisururo@yahoo.co.kr
- Publication Type:Original Article
- Keywords:
Benign prostatic hyperplasia;
Prostate-specific antigen;
Prostate volume
- MeSH:
Biopsy;
Humans;
Linear Models;
Male;
Prostate*;
Prostate-Specific Antigen*;
Prostatic Hyperplasia*;
Prostatic Neoplasms;
Urinary Tract
- From:Journal of the Korean Continence Society
2006;10(2):165-170
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: The purpose of this study was to assess the utility of total prostate-specific antigen(PSA) as a predictor of the prostatic volume in men with symptomatic benign prostate hyperplasia(BPH). MATERIALS AND METHODS: From 1999 to 2003, data were collected from 942 patients complaining of lower urinary tract symptoms(LUTS). Baseline prostatic volume(PV) and serum PSA were measured using transrectal sonography and ELSA-PSA2 kit. Patients with a history of prostate surgery, prostatic cancer and conditions other than BPH at baseline were excluded. Transrectal prostatic biopsy was performed in 162 of patients with a serum PSA >4.0 ng/ml to exclude prostatic cancer. A log-transformed linear regression model was used to estimate threshold PVs in men with BPH, and to select the optimal serum PSA cut-off values. RESULTS: The analyses included 942 patients with a mean age of 63.8 years, mean baseline PV 29.59 ml, and mean baseline PSA value 2.37 ng/ml. PV as well as serum PSA increased with age. Linear regression analyses showed that PV and serum PSA have an age-dependent log-linear relationship. Optimal serum PSA cut-off values for the overall study population irrespective of age was 1.7 ng/ml (AUC: 0.800+/-0.053) to detect PV >30 ml and 2.2 ng/ml (AUC: 0.805+/-0.027) to detect PV >40 ml. The age-specific criteria for detecting men with prostate glands exceeding 40 ml are PSA >1.9 ng/ml (AUC: 0.800+/-0.053), >2.2 ng/ml (AUC: 0.805+/-0.027), and >3.4 ng/ml (AUC: 0.763+/-0.039) for men with BPH in their 50 s, 60 s, and 70 s, respectively. CONCLUSION: This study suggests that PV is strongly related to serum PSA in men with BPH and the relationship depends on age. The age-specific criteria for detecting men with prostate glands exceeding 40 ml are PSA >1.9 ng/ml, >2.2 ng/ml, and >3.4 ng/ml for men with BPH in their 50 s, 60 s, and 70 s, respectively. And in the absence of reliable direct measurement of PV, serum PSA can estimate the degree of prostate enlargement accurately to be useful for therapeutics, especially medical management.
